X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (34961) 34961
Newspaper Article (519) 519
Newsletter (484) 484
Magazine Article (124) 124
Book / eBook (81) 81
Book Chapter (78) 78
Web Resource (10) 10
Conference Proceeding (8) 8
Book Review (5) 5
Trade Publication Article (5) 5
Government Document (4) 4
Publication (3) 3
Dissertation (2) 2
Reference (1) 1
Report (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (30430) 30430
female (16595) 16595
male (13311) 13311
skin neoplasms - drug therapy (11704) 11704
middle aged (10622) 10622
oncology (9985) 9985
aged (8835) 8835
skin neoplasms - pathology (8453) 8453
cancer (8298) 8298
dermatology (7955) 7955
adult (7847) 7847
animals (6570) 6570
melanoma (6358) 6358
skin (4928) 4928
skin and connective tissue diseases (4750) 4750
melanoma - drug therapy (4748) 4748
skin cancer (4584) 4584
treatment outcome (4571) 4571
care and treatment (4538) 4538
mice (4191) 4191
antineoplastic agents - therapeutic use (4037) 4037
tumors (3769) 3769
cell line, tumor (3672) 3672
breast cancer (3602) 3602
metastasis (3498) 3498
chemotherapy (3478) 3478
research (3367) 3367
aged, 80 and over (3350) 3350
melanoma - pathology (3099) 3099
therapy (2975) 2975
apoptosis (2717) 2717
expression (2650) 2650
health aspects (2607) 2607
prognosis (2562) 2562
surgery (2514) 2514
skin neoplasms - therapy (2423) 2423
antineoplastic combined chemotherapy protocols - therapeutic use (2403) 2403
breast neoplasms - drug therapy (2301) 2301
analysis (2268) 2268
risk factors (2184) 2184
cancer therapies (2171) 2171
medicine (2094) 2094
drug therapy (2048) 2048
immunotherapy (2047) 2047
research article (2023) 2023
skin neoplasms - diagnosis (2018) 2018
cell biology (1987) 1987
breast neoplasms - pathology (1957) 1957
neoplasms (1933) 1933
skin neoplasms - genetics (1922) 1922
mutation (1920) 1920
patients (1859) 1859
skin neoplasms - metabolism (1857) 1857
retrospective studies (1844) 1844
skin - pathology (1827) 1827
follow-up studies (1806) 1806
neoplasm staging (1739) 1739
antineoplastic agents - adverse effects (1717) 1717
immunohistochemistry (1707) 1707
diagnosis (1696) 1696
survival (1695) 1695
proteins (1654) 1654
gene expression (1651) 1651
antineoplastic agents - administration & dosage (1623) 1623
antineoplastic agents - pharmacology (1617) 1617
medicine & public health (1601) 1601
biopsy (1590) 1590
time factors (1569) 1569
skin neoplasms - surgery (1519) 1519
neoplasm metastasis (1504) 1504
adolescent (1491) 1491
combined modality therapy (1486) 1486
genetic aspects (1482) 1482
skin neoplasms - immunology (1437) 1437
development and progression (1428) 1428
multidisciplinary sciences (1400) 1400
signal transduction (1378) 1378
kinases (1376) 1376
melanoma - genetics (1364) 1364
medical research (1358) 1358
melanoma - secondary (1321) 1321
pharmacology & pharmacy (1298) 1298
breast neoplasms - metabolism (1287) 1287
diagnosis, differential (1286) 1286
metastases (1283) 1283
metastatic melanoma (1276) 1276
medicine, research & experimental (1271) 1271
skin neoplasms - etiology (1268) 1268
squamous cell carcinoma (1267) 1267
cells (1259) 1259
malignant-melanoma (1239) 1239
apoptosis - drug effects (1238) 1238
biochemistry & molecular biology (1237) 1237
carcinoma (1221) 1221
carcinoma, basal cell - drug therapy (1211) 1211
cell proliferation - drug effects (1207) 1207
melanoma - therapy (1189) 1189
immunology (1187) 1187
studies (1187) 1187
neoplasms - drug therapy (1185) 1185
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (22) 22
Online Resources - Online (8) 8
Scarborough Hospital - General (5) 5
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (5) 5
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
St. Michael's Hospital - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Lakeridge Health Sciences - Oshawa (2) 2
New College (Ivey) - Stacks (2) 2
St. Michael's Hospital - Online (2) 2
UofT at Mississauga - Stacks (2) 2
Women's College Hospital - Reference (2) 2
Credit Valley Hospital - Online (1) 1
Credit Valley Hospital - Reserve desk (1) 1
Credit Valley Hospital - Stacks (1) 1
Humber River Regional Hospital - Church Stacks (1) 1
Lakeridge Health Sciences - Pharmacy (1) 1
Online (1) 1
Pharmacy (1) 1
Reference (1) 1
Robarts - Stacks (1) 1
St Josephs Health Centre - Stacks (1) 1
Sunnybrook Health Sciences Centre - Holland Reference (1) 1
Sunnybrook Health Sciences Centre - Online (1) 1
Trillium Health Centre - Reserve desk (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (34017) 34017
German (788) 788
French (604) 604
Japanese (298) 298
Russian (214) 214
Spanish (163) 163
Italian (93) 93
Polish (87) 87
Chinese (54) 54
Dutch (37) 37
Hungarian (34) 34
Czech (25) 25
Danish (24) 24
Swedish (18) 18
Portuguese (17) 17
Hebrew (15) 15
Norwegian (14) 14
Finnish (6) 6
Korean (5) 5
Serbian (5) 5
Turkish (5) 5
Arabic (3) 3
Romanian (3) 3
Slovak (3) 3
Ukrainian (3) 3
Bulgarian (2) 2
Croatian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Pathology, ISSN 0002-9440, 2010, Volume 177, Issue 4, pp. 1647 - 1656
Phosphatase and tensin homolog (PTEN) is a key modulator of trastuzumab sensitivity in HER2-overexpressing breast cancer. Because PTEN opposes the downstream... 
ADJUVANT CHEMOTHERAPY | INHIBITION | THERAPY | PROTEIN | HUMAN-BREAST-CANCER | PATHWAY | MUTATIONS | PATHOLOGY | RECEPTORS | TRASTUZUMAB RESISTANCE | EXPRESSION | Lung Neoplasms - drug therapy | Receptors, Estrogen - metabolism | Receptor, ErbB-2 - genetics | Lung Neoplasms - mortality | Humans | Middle Aged | Bone Neoplasms - secondary | Antibodies, Monoclonal - therapeutic use | Immunoenzyme Techniques | Receptors, Progesterone - metabolism | Young Adult | Carcinoma, Ductal, Breast - drug therapy | Brain Neoplasms - mortality | Liver Neoplasms - secondary | Proto-Oncogene Proteins c-akt - metabolism | Carcinoma, Ductal, Breast - metabolism | PTEN Phosphohydrolase - genetics | Ribosomal Protein S6 Kinases, 70-kDa - metabolism | Survival Rate | Lymphatic Metastasis | Brain Neoplasms - drug therapy | Mutation - genetics | Breast Neoplasms - drug therapy | Class I Phosphatidylinositol 3-Kinases | Carcinoma, Lobular - metabolism | Trastuzumab | Bone Neoplasms - mortality | Phosphorylation | Prognosis | Receptor, ErbB-2 - metabolism | Phosphatidylinositol 3-Kinases - metabolism | Liver Neoplasms - mortality | Carcinoma, Ductal, Breast - mortality | Carcinoma, Lobular - mortality | Breast Neoplasms - metabolism | Antibodies, Monoclonal, Humanized | Brain Neoplasms - secondary | In Situ Hybridization | Lung Neoplasms - secondary | Adult | Female | Bone Neoplasms - drug therapy | Neoplasm Invasiveness | Liver Neoplasms - drug therapy | PTEN Phosphohydrolase - metabolism | Phosphatidylinositol 3-Kinases - genetics | Breast Neoplasms - mortality | Aged | Carcinoma, Lobular - drug therapy | Regular
Journal Article
BMC cancer, ISSN 1471-2407, 2006, Volume 6, Issue 1, pp. 225 - 225
Background: HER2/neu overexpression is linked to promotion of angiogenesis in breast cancer. We therefore tested the activity of the combination of Trastuzumab... 
PROTEIN | ANGIOGENESIS | ONCOLOGY | NEU ONCOGENE | EPIDERMAL-GROWTH-FACTOR | IN-VIVO | PHASE-II | MONOCLONAL-ANTIBODY | ANTITUMOR-ACTIVITY | FACTOR RECEPTOR | PLUS | Lung Neoplasms - drug therapy | Cyclophosphamide - administration & dosage | Humans | Middle Aged | Neoplasm Proteins - immunology | Bone Neoplasms - secondary | Antibodies, Monoclonal - therapeutic use | Neoplasm Proteins - antagonists & inhibitors | Cyclophosphamide - adverse effects | Bone Neoplasms - blood supply | Leukopenia - chemically induced | Receptor, ErbB-2 - antagonists & inhibitors | Receptor, ErbB-2 - immunology | Liver Neoplasms - secondary | Combined Modality Therapy | Lung Neoplasms - therapy | Lymphatic Metastasis | Breast Neoplasms - blood supply | Brain Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Remission Induction | Methotrexate - adverse effects | Breast Neoplasms - genetics | Brain Neoplasms - therapy | Immunization, Passive | Methotrexate - administration & dosage | Trastuzumab | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bone Neoplasms - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Brain Neoplasms - blood supply | Liver Neoplasms - therapy | Ventricular Dysfunction, Left - chemically induced | Breast Neoplasms - therapy | Antibodies, Monoclonal, Humanized | Brain Neoplasms - secondary | Lung Neoplasms - secondary | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Bone Neoplasms - drug therapy | Neutropenia - chemically induced | Lung Neoplasms - blood supply | Drug Administration Schedule | Liver Neoplasms - drug therapy | Treatment Outcome | Gene Amplification | Liver Neoplasms - blood supply | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Genes, erbB-2 | Aged
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2009, Volume 27, Issue 33, pp. 5538 - 5546
Purpose Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial... 
EFFICACY | ONCOLOGY | RANDOMIZED PHASE-II | TAMOXIFEN RESISTANCE | GROWTH | MCF-7 CELLS | COMBINATION | INHIBITOR | EXPRESSION | ESTROGEN-RECEPTOR | PLUS | Triazoles - administration & dosage | Triazoles - adverse effects | Postmenopause - drug effects | Receptors, Estrogen - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma - mortality | Receptors, Progesterone - genetics | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Invasiveness - pathology | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma - pathology | Carcinoma - secondary | Carcinoma - drug therapy | Receptors, Estrogen - genetics | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Biomarkers, Tumor - analysis | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - pathology | Quinazolines - adverse effects | Survival Analysis | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Carcinoma - metabolism | Neoplasm Staging | Nitriles - adverse effects | Index Medicus | Carcinoma | Quinazolines | Breast Neoplasms | Life Sciences | Immunology | Triazoles | Postmenopause | Nitriles | Antineoplastic Agents, Hormonal | Tumor Markers, Biological | Receptors, Estrogen | Neoplasm Invasiveness | Antineoplastic Combined Chemotherapy Protocols | Receptor, erbB-2 | Receptors, Progesterone | Kaplan-Meiers Estimate
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 738 - 746
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2008, Volume 26, Issue 32, pp. 5269 - 5274
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 7, pp. 976 - 983
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2010, Volume 77, Issue 3, pp. 655 - 661
... standard of care, WBRT, is appropriate as the primary treatment of all patients with BMs instead of reserving WBRT for later salvage therapy, as needed... 
Radiology | Hematology, Oncology and Palliative Medicine | radiotherapy | Brain metastases | prognosis | stereotactic radiosurgery | COST-EFFECTIVENESS | PARTITIONING ANALYSIS RPA | RADIATION-THERAPY | TRIAL | ONCOLOGY | NEUROCOGNITIVE FUNCTION | RANDOMIZED PHASE-III | ACCELERATED-FRACTIONATION | SINGLE METASTASES | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Carcinoma, Non-Small-Cell Lung - radiotherapy | Gastrointestinal Neoplasms | Prognosis | Age Factors | Humans | Middle Aged | Lung Neoplasms | Small Cell Lung Carcinoma - drug therapy | Small Cell Lung Carcinoma - secondary | Brain Neoplasms - secondary | Carcinoma, Non-Small-Cell Lung - secondary | Karnofsky Performance Status | Small Cell Lung Carcinoma - radiotherapy | Retrospective Studies | Brain Neoplasms - radiotherapy | Carcinoma, Renal Cell - drug therapy | Kidney Neoplasms | Brain Neoplasms - diagnosis | Melanoma - radiotherapy | Treatment Outcome | Brain Neoplasms - drug therapy | Melanoma - secondary | Carcinoma, Renal Cell - radiotherapy | Analysis of Variance | Carcinoma, Renal Cell - secondary | Melanoma - drug therapy | Skin Neoplasms | Selection Bias | Aged | Combined Modality Therapy - methods | Carcinoma, Non-Small-Cell Lung - drug therapy | Care and treatment | Metastasis | Patient outcomes | Analysis | SURGERY | METASTASES | NERVOUS SYSTEM | CENTRAL NERVOUS SYSTEM | MEDICINE | NUCLEAR MEDICINE | ORGANS | THERAPY | RADIOLOGY AND NUCLEAR MEDICINE | RADIOTHERAPY | BODY | BRAIN | RADIOLOGY
Journal Article
Veterinary & comparative oncology, ISSN 1476-5810, 2012, Volume 10, Issue 3, pp. 194 - 205
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 10, pp. 1386 - 1396
Journal Article